Vanda Pharmaceuticals forecasts $240 million to $290 million in 2026 revenue, including $10 million to $30 million from NEREUS sales

seekingalpha.com

Vanda Pharmaceuticals projects $240 million to $290 million in 2026 revenue, anticipating $10 million to $30 million from its new NEREUS product. The company reported strong Q1 2026 performance, including 26% year-over-year growth in Fanapt sales and the U.S. launch of NEREUS with a direct-to-consumer platform. Vanda also received FDA approval for BYSANTI and is addressing key risks.


With a significance score of 1.6, this news ranks in the top 30% of today's 31157 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Vanda Pharmaceuticals forecasts $240 million to $290 million in 2026 revenue, including $10 million to $30 million from NEREUS sales | News Minimalist